Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Merck's HPV vaccine Gardasil 9 meets efficacy goals in trial involving Japanese males 16-26 years old, reducing HPV ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The US Department of Agriculture (USDA) has taken a significant step towards the approval of an H5N1 avian flu vaccine for ...

A recent decision by USDA could pave the way for an H5N1 avian flu vaccine for dairy cows by as early as the first quarter of ...

Merck's strong entrenchment in vaccines adds a layer of competitive protection from intellectual property and cost advantages, as the company's large-scale production enables a lower cost base ...

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

According to GlobalData, the recombinant vesicular stomatitis virus – Zaire Ebola virus (rVSV-ZEBOV) vaccine is marketed by Merck under the name Ervebo. It has been available in the US and EU ...